<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.54.0" />
  <meta name="author" content="Dr. med. Wojciech Francuzik">

  
  
  
  
    
      
    
  
  <meta name="description" content="**Background**: Venom-induced anaphylaxis (VIA) is a common, potentially life-threatening hypersensitivity reaction associated with (1) a specific symptom profile, 2) specific cofactors, and 3) specific management. Identifying the differences in phenotypes of anaphylaxis is crucial for future management guidelines and development of a personalized medicine approach.
**Objective**: This study aimed to evaluate the phenotype and risk factors of VIA.
**Methods**: Using data from the European Anaphylaxis Registry (12,874 cases), we identified 3,612 patients with VIA and analyzed their cases in comparison with sex- and age-matched anaphylaxis cases triggered by other elicitors (non-VIA cases [n = 3,605]).
**Results**: VIA more frequently involved more than 3 organ systems and was associated with cardiovascular symptoms. The absence of skin symptoms during anaphylaxis was correlated with baseline serum tryptase level and was associated with an increased risk of a severe reaction. Intramuscular or intravenous epinephrine was administered significantly less often in VIA, in particular, in patients without a history of anaphylaxis. A baseline serum tryptase level within the upper normal range (8-11.5 ng/mL) was more frequently associated with severe anaphylaxis.
**Conclusion**: Using a large cohort of VIA cases, we have validated that patients with intermediate baseline serum tryptase levels (8-11 ng/mL) and without skin involvement have a higher risk of severe VIA. Patients receiving β-blockers or angiotensin-converting enzyme inhibitors had a higher risk of developing severe cardiovascular symptoms (including cardiac arrest) in VIA and non-VIA cases. Patients experiencing VIA received epinephrine less frequently than did cases with non-VIA.
**Keywords**: Anaphylaxis; Hymenoptera; epinephrine (adrenaline); insect venom allergy; β-blockers.">

  
  <link rel="alternate" hreflang="en-us" href="https://wolass.github.io/publication/vanomanaphylaxis/">

  


  

  
  
  <meta name="theme-color" content="#0095eb">
  
  
  
  
    
  
  
    
    
      
        <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
      
    
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.1/css/academicons.min.css" integrity="sha512-NThgw3XKQ1absAahW6to7Ey42uycrVvfNfyjqcFNgCmOCQ5AR4AO0SiXrN+8ZtYeappp56lk1WtvjVmEa+VR6A==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.2.0/leaflet.css" integrity="sha512-M2wvCLH6DSRazYeZRIm1JnYyh22purTM+FDB5CsyxtQJYeKq83arPe5wgbNmcFXGqiSH2XR8dT/fJISVA1r/zQ==" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  

  
    <script>
      window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
      ga('create', 'UA-102587208-1', 'auto');
      ga('require', 'eventTracker');
      ga('require', 'outboundLinkTracker');
      ga('require', 'urlChangeTracker');
      ga('send', 'pageview');
    </script>
    <script async src="//www.google-analytics.com/analytics.js"></script>
    
    <script async src="https://cdnjs.cloudflare.com/ajax/libs/autotrack/2.4.1/autotrack.js" integrity="sha512-HUmooslVKj4m6OBu0OgzjXXr+QuFYy/k7eLI5jdeEy/F4RSgMn6XRWRGkFi5IFaFgy7uFTkegp3Z0XnJf3Jq+g==" crossorigin="anonymous"></script>
    
  

  
  <link rel="alternate" href="https://wolass.github.io/index.xml" type="application/rss+xml" title="Wojciech Francuzik">
  <link rel="feed" href="https://wolass.github.io/index.xml" type="application/rss+xml" title="Wojciech Francuzik">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="https://wolass.github.io/publication/vanomanaphylaxis/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="twitter:site" content="@wolass">
  <meta property="twitter:creator" content="@wolass">
  
  <meta property="og:site_name" content="Wojciech Francuzik">
  <meta property="og:url" content="https://wolass.github.io/publication/vanomanaphylaxis/">
  <meta property="og:title" content="Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry | Wojciech Francuzik">
  <meta property="og:description" content="**Background**: Venom-induced anaphylaxis (VIA) is a common, potentially life-threatening hypersensitivity reaction associated with (1) a specific symptom profile, 2) specific cofactors, and 3) specific management. Identifying the differences in phenotypes of anaphylaxis is crucial for future management guidelines and development of a personalized medicine approach.
**Objective**: This study aimed to evaluate the phenotype and risk factors of VIA.
**Methods**: Using data from the European Anaphylaxis Registry (12,874 cases), we identified 3,612 patients with VIA and analyzed their cases in comparison with sex- and age-matched anaphylaxis cases triggered by other elicitors (non-VIA cases [n = 3,605]).
**Results**: VIA more frequently involved more than 3 organ systems and was associated with cardiovascular symptoms. The absence of skin symptoms during anaphylaxis was correlated with baseline serum tryptase level and was associated with an increased risk of a severe reaction. Intramuscular or intravenous epinephrine was administered significantly less often in VIA, in particular, in patients without a history of anaphylaxis. A baseline serum tryptase level within the upper normal range (8-11.5 ng/mL) was more frequently associated with severe anaphylaxis.
**Conclusion**: Using a large cohort of VIA cases, we have validated that patients with intermediate baseline serum tryptase levels (8-11 ng/mL) and without skin involvement have a higher risk of severe VIA. Patients receiving β-blockers or angiotensin-converting enzyme inhibitors had a higher risk of developing severe cardiovascular symptoms (including cardiac arrest) in VIA and non-VIA cases. Patients experiencing VIA received epinephrine less frequently than did cases with non-VIA.
**Keywords**: Anaphylaxis; Hymenoptera; epinephrine (adrenaline); insect venom allergy; β-blockers.">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2021-02-01T00:00:00&#43;00:00">
  
  <meta property="article:modified_time" content="2021-02-01T00:00:00&#43;00:00">
  

  

  <title>Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry | Wojciech Francuzik</title>

</head>
<body id="top" data-spy="scroll" data-target="#toc" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/">Wojciech Francuzik</a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      
      <ul class="nav navbar-nav navbar-right">
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#about">
            
            <span>Home</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#publications_selected">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#posts">
            
            <span>Posts</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#projects">
            
            <span>Projects</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        
      

      
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/CreativeWork">

  


  <div class="article-container">
    <h1 itemprop="name">Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry</h1>
    <span class="pub-authors" itemprop="author">
      
      Wojciech Francuzik, Franziska Ruëff, Andrea Bauer, Maria Beatrice Bilò, Victoria Cardona, George Christoff, Sabine Dölle-Bierke, Luis Ensina, Montserrat Fernández Rivas, Thomas Hawranek, Jonathan O&rsquo;B Hourihane, Thilo Jakob, Nicos G Papadopoulos, Claudia Pföhler, Iwona Poziomkowska-Gęsicka, Xavier Van der Brempt, Kathrin Scherer Hofmeier, Regina Treudler, Nicola Wagner, Bettina Wedi, Margitta Worm
      
    </span>
    <span class="pull-right">
      
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Phenotype%20and%20risk%20factors%20of%20venom-induced%20anaphylaxis%3a%20A%20case-control%20study%20of%20the%20European%20Anaphylaxis%20Registry&amp;url=https%3a%2f%2fwolass.github.io%2fpublication%2fvanomanaphylaxis%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=https%3a%2f%2fwolass.github.io%2fpublication%2fvanomanaphylaxis%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-facebook"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https%3a%2f%2fwolass.github.io%2fpublication%2fvanomanaphylaxis%2f&amp;title=Phenotype%20and%20risk%20factors%20of%20venom-induced%20anaphylaxis%3a%20A%20case-control%20study%20of%20the%20European%20Anaphylaxis%20Registry"
         target="_blank" rel="noopener">
        <i class="fa fa-linkedin"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=https%3a%2f%2fwolass.github.io%2fpublication%2fvanomanaphylaxis%2f&amp;title=Phenotype%20and%20risk%20factors%20of%20venom-induced%20anaphylaxis%3a%20A%20case-control%20study%20of%20the%20European%20Anaphylaxis%20Registry"
         target="_blank" rel="noopener">
        <i class="fa fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Phenotype%20and%20risk%20factors%20of%20venom-induced%20anaphylaxis%3a%20A%20case-control%20study%20of%20the%20European%20Anaphylaxis%20Registry&amp;body=https%3a%2f%2fwolass.github.io%2fpublication%2fvanomanaphylaxis%2f">
        <i class="fa fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


    </span>

    

    
    <h3>Abstract</h3>
    <p class="pub-abstract" itemprop="text"><strong>Background</strong>: Venom-induced anaphylaxis (VIA) is a common, potentially life-threatening hypersensitivity reaction associated with (1) a specific symptom profile, 2) specific cofactors, and 3) specific management. Identifying the differences in phenotypes of anaphylaxis is crucial for future management guidelines and development of a personalized medicine approach.
<strong>Objective</strong>: This study aimed to evaluate the phenotype and risk factors of VIA.
<strong>Methods</strong>: Using data from the European Anaphylaxis Registry (12,874 cases), we identified 3,612 patients with VIA and analyzed their cases in comparison with sex- and age-matched anaphylaxis cases triggered by other elicitors (non-VIA cases [n = 3,605]).
<strong>Results</strong>: VIA more frequently involved more than 3 organ systems and was associated with cardiovascular symptoms. The absence of skin symptoms during anaphylaxis was correlated with baseline serum tryptase level and was associated with an increased risk of a severe reaction. Intramuscular or intravenous epinephrine was administered significantly less often in VIA, in particular, in patients without a history of anaphylaxis. A baseline serum tryptase level within the upper normal range (8-11.5 ng/mL) was more frequently associated with severe anaphylaxis.
<strong>Conclusion</strong>: Using a large cohort of VIA cases, we have validated that patients with intermediate baseline serum tryptase levels (8-11 ng/mL) and without skin involvement have a higher risk of severe VIA. Patients receiving β-blockers or angiotensin-converting enzyme inhibitors had a higher risk of developing severe cardiovascular symptoms (including cardiac arrest) in VIA and non-VIA cases. Patients experiencing VIA received epinephrine less frequently than did cases with non-VIA.
<strong>Keywords</strong>: Anaphylaxis; Hymenoptera; epinephrine (adrenaline); insect venom allergy; β-blockers.</p>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Type</div>
          <div class="col-xs-12 col-sm-9">
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Publication</div>
          <div class="col-xs-12 col-sm-9">Journal of Allergy and Clinical Immunology</div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Date</div>
          <div class="col-xs-12 col-sm-9" itemprop="datePublished">
            February, 2021
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row" style="padding-top: 10px">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading" style="line-height:34px;">Links</div>
          <div class="col-xs-12 col-sm-9">

            




<a class="btn btn-primary btn-outline" href="https://doi.org/10.1016/j.jaci.2020.06.008" target="_blank" rel="noopener">
  PDF
</a>




<button type="button" class="btn btn-primary btn-outline js-cite-modal"
        data-filename="/files/citations/vanomanaphylaxis.bib">
  Cite
</button>













          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="space-below"></div>

    <div class="article-style"></div>

    





  </div>
</div>



<footer class="site-footer">
  <div class="container">
    <p class="powered-by">

      CC-BY 4.0; 2017 Wojciech Francuzik &middot; 

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.2.0/leaflet.js" integrity="sha512-lInM/apFSqyy1o6s89K4iQUKg6ppXEgsVxT35HbzUupEVRh2Eu9Wdl4tHj7dZO0s1uvplcYGmt3498TtHq+log==" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    
      
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
      

      

      

      <script>hljs.initHighlightingOnLoad();</script>
    

    
    

  </body>
</html>

